论文部分内容阅读
TRAIL,即肿瘤坏死因子相关凋亡诱导配体,于1995年由W iley等发现并命名。其结构与TNF类似,呈典型的Ⅱ型跨膜蛋白特征,属于TNF超家族成员。TRAIL与其受体结合后,通过胞内信号传导通路,发挥诱导细胞凋亡等多种生物学功能。TRAIL可表达于人体内不同脏器来源的细胞,在多种疾病的演变进程中发挥着重要的作用。了解TRAIL基因多态性与临床疾病的相关性,为从基因水平对疾病发生、发展以及预后进行深层探讨提供了一定的理论基础。
TRAIL, a tumor necrosis factor related apoptosis-inducing ligand, was discovered and named by Wiley et al. In 1995. Its structure similar to TNF, a typical type II transmembrane protein features, belongs to the TNF superfamily member. After TRAIL binds with its receptor, it can exert various biological functions such as inducing cell apoptosis through the intracellular signal transduction pathway. TRAIL can be expressed in different organ-derived cells in the human body and play an important role in the progression of various diseases. To understand the relationship between TRAIL gene polymorphism and clinical disease, and to provide a theoretical basis for further exploration of the occurrence, development and prognosis of the disease from the gene level.